Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR.
Javitt DC, et al.
Schizophr Res. 2012 Apr;136(1-3):25-31. doi: 10.1016/j.schres.2011.11.001. Epub 2011 Dec 12.
Schizophr Res. 2012.
PMID: 22169248
Clinical Trial.